Home / Stocks / Abbott India Limited
ABBOTINDIA

Abbott India Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹25,695.0

Change

+225.0 (0.88%)

Open

₹25,595.0

Prev. Close

₹25,470.0

Day High

₹25,940.0

Day Low

₹25,430.0

Volume Analysis

Traded

11,674

Delivered

7,463

Delivery %

63.93%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (27.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year EPS growth (17.8%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹26,456.66 ₹26,198.33 ₹25,946.66 ₹25,688.33 ₹25,436.66 ₹25,178.33 ₹24,926.66
Fibonacci ₹26,198.33 ₹26,003.51 ₹25,883.15 ₹25,688.33 ₹25,493.51 ₹25,373.15 ₹25,178.33
Camarilla ₹25,835.25 ₹25,788.5 ₹25,741.75 ₹25,688.33 ₹25,648.25 ₹25,601.5 ₹25,554.75

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-9.79%

1 Week

-3.4%

1 Month

+0.06%

3 Months

-2.04%

6 Months

-7.67%

1 Year

-13.15%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

36.43%

Net margin 22.4% × asset turnover 1.17x × equity multiplier 1.39x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Abbott India Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 78/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (36/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (27.0%). Strong 3-year EPS growth (17.8%).

TopFund Score — Fundamentals Quality

78/100 — Good

Data confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

68

Cash Flow

88

Corporate Governance

56

Institutional Ownership

36

Business Quality

100

Risk & Volatility

70

Liquidity

82

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Advertisement of the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2026.

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 1,494 1,437 1,439 1,558 1,633 1,614 1,605 1,738 1,757 1,724 1,710 1,814 1,951
Expenses + 1,113 1,049 1,109 1,167 1,194 1,178 1,176 1,293 1,255 1,261 1,229 1,291 1,383
Operating Profit 381 388 330 391 439 436 429 446 502 463 481 522 568
OPM % 25.0% 27.0% 23.0% 25.0% 27.0% 27.0% 27.0% 26.0% 29.0% 27.0% 28.0% 29.0% 29.0%
Other Income + 56 56 81 67 60 72 76 73 70 70 76 75 68
Interest 3 3 3 3 2 2 4 6 8 5 6 6 6
Depreciation 18 18 18 18 18 18 18 19 19 19 19 20 19
Profit before tax 415 422 390 437 479 488 483 493 546 509 531 572 610
Tax % 25.0% 26.0% 26.0% 25.0% 25.0% 26.0% 24.0% 26.0% 24.0% 26.0% 26.0% 25.0% 26.0%
Net Profit + 313 311 287 328 359 361 367 366 415 376 395 429 453
EPS in Rs 147 146 135 154 169 170 173 172 195 177 186 202 213
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 8 9 7 5 9 12 12 12 8 7 7 4 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 2,289 2,614 2,903 3,298 3,679 4,093 4,310 4,919 5,349 5,849 6,409 6,929
Expenses + 1,977 2,250 2,505 2,774 3,074 3,336 3,388 3,832 4,143 4,396 4,714 5,037
Operating Profit 312 365 398 525 605 757 922 1,088 1,206 1,453 1,695 1,892
OPM % 14.0% 14.0% 14.0% 16.0% 16.0% 18.0% 21.0% 22.0% 23.0% 25.0% 26.0% 27.0%
Other Income + 48 50 57 117 113 114 81 77 154 248 275 288
Interest 0 3 2 4 2 9 18 19 16 12 11 25
Depreciation 15 14 16 16 17 60 58 66 70 71 72 76
Profit before tax 344 398 436 621 699 803 926 1,080 1,274 1,618 1,887 2,079
Tax % 34.0% 36.0% 37.0% 35.0% 36.0% 26.0% 25.0% 26.0% 25.0% 26.0% 25.0% 25.0%
Net Profit + 229 255 277 401 450 593 691 799 949 1,201 1,414 1,552
EPS in Rs 108 120 130 189 212 279 325 376 447 565 666 730
Dividend Payout % 29.0% 29.0% 31.0% 29.0% 31.0% 90.0% 85.0% 73.0% 73.0% 73.0% 71.0% 90.0%
Sales growth 1 14 11 14 12 11 5 14 9 9 10 8

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 916 1,174 1,366 1,672 1,987 2,410 2,581 2,799 3,167 3,678 4,212 4,753 4,249
Borrowings + 0 0 0 0 0 175 153 152 113 83 197 172 154
Other Liabilities + 436 421 679 723 932 940 1,086 1,253 1,254 1,411 1,487 1,556 1,500
Total Liabilities 1,374 1,616 2,066 2,416 2,941 3,547 3,840 4,224 4,556 5,193 5,917 6,502 5,925
Fixed Assets + 96 108 110 81 105 270 251 271 237 225 336 331 300
CWIP 4 3 6 2 1 2 1 1 4 10 18 6 12
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 1,274 1,505 1,950 2,333 2,835 3,275 3,589 3,952 4,315 4,958 5,563 6,165 5,613
Total Assets 1,374 1,616 2,066 2,416 2,941 3,547 3,840 4,224 4,556 5,193 5,917 6,502 5,925
Equity Capital 21 21 21 21 21 21 21 21 21 21 21 21 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + 215 249 307 153 499 626 727 948 893 1,213 1,012 1,319
Cash from Investing Activity + -187 -77 -155 -215 -257 -401 -72 -396 -148 -416 182 -371
Cash from Financing Activity + -58 -80 -90 -102 -143 -217 -582 -637 -639 -745 -925 -1,066
Net Cash Flow -30 91 62 -165 99 8 73 -86 107 52 269 -118
Free Cash Flow 199 226 287 180 504 611 704 904 860 1,165 960 1,307
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 106 109 117 68 125 113 104 114 102 111 86 98

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 74.99% → 74.99%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 16.09% 15.92% 16.01% 15.86% 15.85% 15.94% 15.67% 15.74% 15.83% 15.81% 15.85% 15.62%
Promoters 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99%
FII 0.18% 0.18% 0.18% 0.17% 0.17% 0.16% 0.16% 0.16% 0.19% 0.27% 0.38% 0.4%
DII 8.73% 8.91% 8.81% 9.0% 9.01% 8.91% 9.18% 9.11% 9.0% 8.93% 8.77% 8.99%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Abbott India Limited (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Abbott India Limited?

Frequently Asked Questions about Abbott India Limited

Community Sentiment

What are other investors saying about Abbott India Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.